Although the earnings docket is light, a number of speeches from Federal Reserve officials and a slew of data points -- concluding on Friday with the highly anticipated jobs report -- will provide a wealth of information for traders to chew on. Meanwhile, among the few names making their way into the earnings confessional are Ciena Corporation (NYSE:CIEN), Dollar General Corp. (NYSE:DG), VeriFone Systems Inc (NYSE:PAY), and Yingli Green Energy Hold. Co. Ltd. (ADR) (NYSE:YGE).

Below is a brief list of some key market events scheduled for the upcoming week. All earnings dates listed below are tentative and subject to change. Please check with each company's respective website for official reporting dates.

Monday, June 1

Personal income and spending, Markit's purchasing managers index (PMI), the Institute for Supply Management's (ISM) manufacturing index, and construction spending will kick off a busy week of economic data. A number of Fed speakers will take the stage throughout the week, as well, with Boston Fed President Eric Rosengren kicking things off Monday morning. There are no earnings reports of note.


Tuesday, June 2

Auto sales and factory orders will be released on Tuesday. Ambarella (AMBA), Conn's (CONN), Cracker Barrel (CBRL), DG, Guess? (GES), and Medtronic (MDT) will report earnings.

Wednesday, June 3

Jobs data starts to roll in on Wednesday, with ADP's employment report. International trade data, the ISM's non-manufacturing index, the weekly crude inventories update, and the Fed's Beige Book are also slated for release. Chicago Fed President Charles Evans and St. Louis Fed President James Bullard are scheduled to speak. Five Below (FIVE) and Vera Bradley (VRA) will step up to the earnings plate.

Thursday, June 4

Thursday's docket features weekly jobless claims, productivity and labor costs, as well as a speech from Fed Governor Daniel Tarullo. Analogic (ALOG), CIEN, Diamond Foods (DMND), J. M. Smucker (SJM), Joy Global (JOY), Lands' End (LE), PAY, and Zumiez (ZUMZ) are scheduled to unveil their earnings reports.


Friday, June 5

The Labor Department's nonfarm payrolls report will be in focus on Friday, as will an early afternoon speech from New York Fed President William Dudley. YGE will tell all in the earnings confessional. Additionally, Friday marks the deadline for Greece's first payment of four in June to the International Monetary Fund (IMF).

Analysts are weighing in today on video game retailer GameStop Corp. (NYSE:GME), biotech firm Heron Therapeutics Inc (NASDAQ:HRTX), and network services provider Infoblox Inc (NYSE:BLOX). Here's a quick roundup of today's bullish brokerage notes on GME, HRTX, and BLOX.

• The company's first-quarter earnings beat and promising current-quarter forecast have GME gaining ahead of the open. The shares are pointed 6.8% higher, poised to add to their 21.1% year-to-date lead, after settling at $40.92 yesterday. On the Street, Wedbush and Ascendiant Capital each raised their price targets this morning, to $52 and $46, respectively. Most analysts are already bullishly aligned, with 11 of 15 calling GameStop Corp. a "buy" or better. Many traders have the opposite view. A stunning 44.8% of GME's float is sold short, which would take over two months to repurchase, at its average daily volumes.


• HRTX is exploding in pre-market trading, set to add 38% -- and hit four-year highs -- after the company announced its nausea drug achieved positive top-line results in its Phase 3 study. JMP Securities has since weighed in, raising its price target to $25 from $23. The Street is already behind the stock, as all four covering brokerage firms rate it a "strong buy." Additionally, Heron Therapeutics Inc's average 12-month price target of $25.80 is more than double that of the stock's close yesterday at $12.35. The shares have earned the bullish feedback, though. HRTX has added almost 23% in 2015.


• Strong fiscal third-quarter numbers have BLOX moving higher in electronic trading, last seen up 4%. The equity finished at $26.32 yesterday -- after hitting an annual high of $26.48 -- and has been stair-stepping higher for since mid-2014, adding over 28% year-over-year. Even with these gains, near-term option traders are more put-focused than normal. Infoblox Inc's Schaeffer's put/call open interest ratio (SOIR) stands at 0.53, only 2 percentage points from an annual high. 

Analysts are weighing in today on footwear specialist Deckers Outdoor Corp (NYSE:DECK), fertilizer fiend Potash Corp./Saskatchewan (USA) (NYSE:POT), and offshore drilling issue Transocean LTD (NYSE:RIG). Here's a quick roundup of today's bearish brokerage notes on DECK, POT, and RIG.

• DECK was hit with a round of negative analyst notes today, following last night's poorly received fiscal fourth-quarter numbers. Specifically, Jefferies cut its price target to $105 from $110, Janney trimmed its fair value to $80 from $82, and Credit Suisse lowered its outlook to $77 from $82 -- though Susquehanna raised its price target to $86 from $83. Ahead of the bell, Deckers Outdoor Corp is off 1.7% -- business as usual for a stock that's dropped nearly 22% in 2015 to trade at $71.20. Traders at the International Securities Exchange (ISE), Chicago Board Options Exchange (CBOE), and NASDAQ OMX PHLX (PHLX) are betting on more downside ahead. DECK's 50-day put/call volume ratio of 1.43 ranks in the 80th annual percentile, meaning traders have had a strong-than-usual appetite for puts over calls. 


• POT is signaling a lower start this morning, after TD Securities downgraded the equity to "hold" from "buy," and lowered its price target to $35 from $39. On the charts, the shares have been churning in the $32-$33.50 range for the last two months, and settled at $32.33 yesterday -- off 14% since their mid-February high at $37.60. Potash Corp./Saskatchewan could be vulnerable to additional negative analyst attention. Eight brokerage firms consider the stock a "buy" or better, compared to nine "holds" and just one "strong sell." Plus, POT's consensus 12-month price target of $45.44 stands at a more than 40% premium to Thursday's close.


• RIG was started with an "underweight" rating and $16 price target at J.P. Morgan Securities. Now, the shares are set to start the day 0.3% lower. Technically speaking, the equity had a disastrous 2014, but has been clawing its way higher this year -- up 3.7% at $19.01, and currently sitting atop its 32-day moving average. However, the brokerage bunch remains exceedingly bearish on Transocean LTD, with all 16 analysts handing out "hold" or worse recommendations. Echoing this, 29.4% of RIG's float is sold short, equating to nearly nine sessions' worth of trading activity, at typical daily levels.

Stock futures are signaling a slow start, as traders digest the preliminary reading on first-quarter gross domestic product (GDP) and keep a cautious eye trained on Greece. Meanwhile, among specific equities in focus are chipmaker Intel Corporation (NASDAQ:INTC), tech titan Google Inc (NASDAQ:GOOGL), and Chinese e-commerce concern Alibaba Group Holding Ltd (NYSE:BABA).

• INTC was one of the leading advancers on the Dow yesterday. The stock appears poised for more of the same in today's session, following reports the firm is close to shutting the door on a deal to purchase Altera Corporation (NASDAQ:ALTR) for about $15 billion. Since the rumors first began in early May, shares of INTC have added more than 4%, and last night, the stock closed at $34.01 -- and secured its first close north of its 160-day moving average since mid-February. In the options pits, traders have shown a growing appetite for long puts over calls in recent weeks. At the International Securities Exchange (ISE), Chicago Board Options Exchange (CBOE), and NASDAQ OMX PHLX (PHLX), for example, Intel Corporation's 10-day put/call volume ratio of 1.47 ranks in the 90th annual percentile. An unwinding of these bearish bets in the face of INTC'S continued rise could spell additional gains.


• GOOGL kicked off its two-day Google I/O conference yesterday, and announced a number of new developments -- mostly to its Android operating system (OS). Specifically, the company unveiled Android M -- its updated OS -- which includes a fingerprint scanner and Android Pay. Additionally, GOOGL said it is teaming up GoPro Inc (NASDAQ:GPRO) to develop a virtual reality camera. On the charts, the stock started the year off strong, but has spent the past few months churning in the $530-to-$580 range, and settled Thursday at $554.18. Analysts have kept the faith, though, and of the 29 brokerage firms covering the shares, 24 maintain a "buy" or better rating, with not a single "sell" to be found. Plus, the average 12-month price target of $638.30 sits in never-before-seen territory. Looking ahead, Google Inc will host its annual shareholder meeting next Wednesday.


• BABA has been making quite the comeback on the charts since hitting a record low of $77.77 in early May, up 16.9% at $90.95. The security looks ready to add to these gains in today's session, amid speculation the company could be joining forces with Yahoo Japan Corp., allowing the latter to expand into the Chinese marketplace. On the sentiment front, Wall Street has been extremely optimistic toward Alibaba Group Holding Ltd. For starters, all 23 analysts covering the shares maintain a "buy" or "strong buy" suggestion. Elsewhere, traders at the ISE, CBOE, and PHLX have bought to open 3.27 calls for each put over the past 10 sessions.

Analysts are weighing in today on smartphone concern BlackBerry Ltd (NASDAQ:BBRY), as well as semiconductor manufacturers Magnachip Semiconductor Corp (NYSE:MX), and Himax Technologies, Inc. (ADR) (NASDAQ:HIMX). Here's a quick look at today's brokerage notes on BBRY, MX, and HIMX.

• There's plenty of buzz surrounding BBRY today, which is down 1.3% at $9.90, after a Morgan Stanley analyst reiterated his "underweight" rating and $7 price target, and said the company's 2016 forecast is "unattainable." This mirrors the general outlook on the Street, where 16 of 19 brokerage firms say the stock is a "hold" or worse. Not only that, but 16.9% of BlackBerry Ltd's float is sold short, representing almost 11 days of trading, at its normal volumes. This widespread pessimism is interesting, considering the shares have added over 30% in the past year. From a contrarian standpoint, this skepticism could benefit BBRY, if it can resume its long-term uptrend.


• Topeka Capital upgraded its rating on MX to "buy" from "hold" today, following the company's impressive showing in the earnings confessional. The stock is still trying to make up ground after its massive mid-February bear gap, but the shares have outperformed the S&P 500 Index (SPX) by nearly 14 percentage points in the past three months. Plus, they're soaring today, last seen 13.5% higher at $7.25. Put buying has still been more popular than normal in recent months. Magnachip Semiconductor Corp's 50-day International Securities Exchange (ISE), Chicago Board Options Exchange (CBOE), and NASDAQ OMX PHLX (PHLX) put/call volume ratio of 0.28 is higher than more than three-fourths of readings from the past year.


• HIMX is 4.8% lower today at $6.22, with a downgrade to "sell" from "neutral" -- and price-target cut to $4 from $5 -- at Chardan Capital weighing on the shares. Specifically, the brokerage firm said Samsung could possibly migrate from HIMX LCD display drivers to AMOLED displays. Even before today, the equity was 19% below its year-to-date breakeven level, and short sellers have been piling on. Short interest increased 52.8% during the two most recent reporting periods, and it would now take over four days to buy back all the shorted shares, at Himax Technologies, Inc.'s average daily volumes. Things are more bullish in HIMX's options pits, though. During the past 50 days at the ISE, CBOE, and PHLX, over 17,000 calls have been bought to open, versus fewer than 400 puts.

Analysts are weighing in today on networking specialist Juniper Networks, Inc. (NYSE:JNPR), furniture retailer Pier 1 Imports Inc (NYSE:PIR), and biopharmaceutical concern Mirati Therapeutics, Inc. (NASDAQ:MRTX). Here's a quick roundup of today's bearish brokerage notes on JNPR, PIR, and MRTX.

• JNPR is off 1.4% ahead of the open, after MKM Partners cut its outlook on the shares to "sell" from "neutral." The downgrade comes despite the equity's 24.6% year-to-date climb to $27.80, or the stock's annual high of $28.26, tagged just last week amid M&A rumors. Most analysts have taken a skeptical approach, with 16 of 24 brokerage firms deeming Juniper Networks, Inc. a "hold." Conversely, option traders have been decidedly bullish on the stock. Over the past 10 days at the International Securities Exchange (ISE), Chicago Board Options Exchange (CBOE), and NASDAQ OMX PHLX (PHLX), nearly 66 calls have been bought to open for every put. This 10-day call/put volume ratio of 65.72 stands higher than all similar readings from the past year.


• Wedbush weighed in on PIR this morning, lowering its grade to "neutral" from "outperform," while also reducing its price target to $12 from $16. The shares have already given back almost 28% in the past 12 months to settle at $12.71 on Friday. Put players have since stepped up, with Pier 1 Imports Inc's Schaeffer's put/call open interest ratio (SOIR) registering at 5.16, meaning put open interest is five times that of call open interest among options that expire in the next three months. Plus, this reading is only 1 percentage point from an annual high, telling us that PIR's near-term option traders are way more put-skewed than normal.


• MRTX is getting annihilated in electronic trading, pointed 20% lower. Traders are reacting to a bearish note from Brean Capital, which lowered its rating to "hold" from "buy," citing lackluster data on MRTX's lung cancer drug. (On the flip side, the stock scored price-target hikes from Jefferies and Wedbush.) The anticipated drop would certainly mark a change of pace for Mirati Therapeutics, Inc., as it has nearly doubled in 2015, hitting an all-time high of $37.43 on Friday, before closing at $36.66. 

Analysts are weighing in on banking giant Citigroup Inc (NYSE:C), beverage behemoth The Coca-Cola Co (NYSE:KO), and biotechnology firm Heron Therapeutics Inc (NASDAQ:HRTX). Here's a quick roundup of today's bullish brokerage notes on C, KO, and HRTX.

• Goldman Sachs upgraded C to "buy" from "neutral," and raised its price target to $61 from $57, saying the market is lowballing the firm's return on earnings forecast. Separately, Citigroup Inc said it is closing the doors at Banamex USA -- its California-based Mexican banking subsidiary -- amid money-laundering accusations. Technically speaking, the stock has been chugging higher since hitting a 2015 low of $46.60 on Jan. 16, up 16%. More recently, though, this upside has stalled out in the $55-to-$55.50 region, with C closing at $54.08 on Friday. Option traders have taken the glass-half-empty approach in recent weeks, and at the International Securities Exchange (ISE), Chicago Board Options Exchange (CBOE), and NASDAQ OMX PHLX (PHLX), the stock's 10-day put/call volume ratio of 0.82 ranks in the 97th annual percentile.

• KO saw its rating raised to "outperform" from "market perform" and its price target bumped to $48 from $44 at BMO -- representing expected upside of 17.2% to last Friday's settlement at $40.96, and a trek into never-before-seen territory. As such, the blue chip is poised to follow the broader Dow into the green today. On the charts, KO has spent most of the past year bouncing between $39 and $45. Option traders have kept the faith, though, per the security's 10-day ISE/CBOE/PHLX call/put volume ratio of 5.21, which rests in the 73rd percentile of its annual range. Simply stated, calls have been bought to open over puts at a faster-than-usual clip.

• Leerink raised its price target on HRTX to $26 from $20 -- an area not seen since March 2010. The bullish brokerage note has shares of Heron Therapeutics Inc up 8% in electronic trading, and on their way to notch a new five-year high. This positive price action only echoes the stock's recent technical showing, with HRTX adding 60% on Friday, thanks to some well-received drug data and upbeat analyst attention -- and roughly doubling in value this year. Against this backdrop, it's not surprising to see the brokerage bunch in HRTX's corner. In fact, all four analysts covering the shares maintain a "strong buy" rating, while the average 12-month price target of $29.60 stands at a 50% premium to last week's settlement at $19.76.

U.S. stocks kicked off the week on a high note, with the major indexes sitting in the black. In company news, today's stocks to watch include software giant Microsoft Corporation (NASDAQ:MSFT), as well as drugmakers Vascular Biogenics Ltd (NASDAQ:VBLT) and Celladon Corp (NASDAQ:CLDN). 

• MSFT announced its Windows 10 operating system will be available globally on Wednesday, July 29. Users of Windows 7 and 8.1 can upgrade to the new version for free. In early trading, Microsoft Corporation shares are 0.7% higher at $47.17, but have struggled longer term -- up less than 2% year-to-date. As such, options traders have been buying to open puts over calls at an accelerated clip in recent months. MSFT's 50-day International Securities Exchange (ISE), Chicago Board Options Exchange (CBOE), and NASDAQ OMX PHLX (PHLX) put/call volume ratio of 0.73 ranks just 12 percentage points from a 12-month peak. Echoing this, the stock's Schaeffer's put/call open interest ratio (SOIR) of 0.79 sits in the put-skewed 70th percentile of its annual range.
  


• VBLT is 7.3% higher at $8.64, thanks to encouraging trial results from its brain tumor drug, VB-111. From a relative-strength perspective, Vascular Biogenics Ltd has outperformed the broader S&P 500 Index (SPX) by 117 percentage points over the last 20 sessions, and is more than 47% higher year-to-date. Not surprisingly, all three analysts tracking the stock rate it a "strong buy," and VBLT's consensus 12-month price target of $13 stands in territory not charted since a mid-February bear gap.


• Finally, CLDN is looking for a strategic partnership or acquisition, following the disappointing performance of its heart drug in a mid-stage trial. The company also named Chief Financial Officer Paul Cleveland as its new CEO, after Krisztina Zsebo resigned from the post. These developments have the equity sitting 12.1% higher at $2.59. Longer term, though, Celladon Corp has performed terribly, shedding 86.7% of its value in 2015. On the sentiment front, each of the four brokerage firms following CLDN consider it a "hold," while its average 12-month price target of $2.33 is roughly in line with current trading levels.
  

Analysts are weighing in on coal concern Peabody Energy Corporation (NYSE:BTU), semiconductor specialist Ambarella Inc (NASDAQ:AMBA), and drugmaker aTyr Pharma Inc (NASDAQ:LIFE). Here's a quick roundup of today's brokerage notes on BTU, AMBA, and LIFE.

• BTU has earned a dreary spot on the Big Board, after Goldman Sachs initiated coverage on the stock with a "sell" rating and a $2 price target, citing concerns over domestic thermal coal demand. At last check, the security was down 6.2% at $3.16, and fresh off a record low of $3.15. Today's negative price action just echoes the withstanding trajectory of a security that's surrendered 80% of its value year-over-year. Peabody Energy Corporation could encounter a fresh wave of selling pressure, too, should any analysts follow in Goldman Sachs' footsteps. Currently, seven out of 17 brokerage firms maintain a "buy" or better rating on the equity, while the average 12-month price target of $7.10 stands at a 125% premium to BTU's present perch.


• Ahead of AMBA's turn in the earnings confessional tomorrow night, Deutsche Bank raised its price target on the stock to $80 from $64. The bullish brokerage note has sent the shares soaring to yet another record high; this time, with AMBA topping out at $93.86. Longer term, the stock has added 85% in 2015, and was last seen lingering near $93.73. In the options pits, speculators have shown an increasing preference for puts over calls among options set to expire in three months or less. Specifically, Ambarella Inc's Schaeffer's put/call open interest ratio (SOIR) has jumped to 1.10 from its May 18 reading of 0.94, and now ranks in the 66th percentile of its annual range.


• Wall Street newcomer LIFE received a bevy of bullish brokerage notes, and has moved 2.1% higher to $23.36 as a result. Both BMO and William Blair, for example, initiated coverage with an "outperform" rating and a $42 price target. Elsewhere, J.P. Morgan Securities started the stock with an "overweight" recommendation and a $44 target price, while Citigroup began coverage with a "buy" suggestion and a $32 price target. Since going public on May 7, aTyr Pharma Inc has tacked on more than 75%, and topped out at a post-IPO peak of $27.82 on May 21.

Skepticism has been running high in Puma Biotechnology Inc's (NYSE:PBYI) options pits for some time. The drugmaker's 10-day put/call volume ratio across the International Securities Exchange (ISE), Chicago Board Options Exchange (CBOE), and NASDAQ OMX PHLX (PHLX) is 3.07 -- with long puts more than tripling calls. What's more, this ratio is perched just 8 percentage points from a 12-month high.

Echoing this skepticism is PBYI's Schaeffer's put/call open interest ratio (SOIR) of 1.80. Not only does this SOIR indicate short-term put open interest nearly doubles call open interest, it also sits in the 90th percentile of its annual range.

These bearish bettors are in luck today, as PBYI's taken a 10% tumble to trade at $175.64 -- and landed on the short-sale restricted list. The shares were also temporarily halted earlier. Potentially pressuring the stock was news that nearly 40% of patients treated with PBYI's breast cancer drug neratinib developed severe diarrhea.

This isn't the first time the cancer treatment has weighed on the shares. PBYI gapped sharply lower on May 14 following the results of another neratinib trial. With today's losses, though, Puma Biotechnology Inc (NYSE:PBYI) is now sitting 7.2% below its year-to-date breakeven mark. Off the charts, the company will hold its investor/analyst meeting this evening.

Analysts are weighing in on restaurant chain Bojangles Inc (NASDAQ:BOJA), financial firm Zions Bancorporation (NASDAQ:ZION), and drugmaker Vical Incorporated (NASDAQ:VICL). Here's a quick roundup of today's bullish brokerage notes on BOJA, ZION, and VICL.

• BOJA -- which began trading publicly in early May -- received a bevy of brokerage notes today. Included in the bunch was a "buy" initiation and $32 price target at Jefferies, as well as an "outperform" suggestion at William Blair, which cited the company's "cult-like following" and early morning sales as its catalyst. However, not all of the notes were optimistic, with Barclays and Piper Jaffray starting coverage with the equivalent of a "neutral" rating and a $27 price target -- a discount to last night's close at $28.01. Since its May 8 open at $26.55, shares of BOJA have added 5.5%. In the short time the stock has been trading options, speculators have shown a distinct preference for long calls over puts, per Bojangles Inc's 10-day International Securities Exchange (ISE), Chicago Board Options Exchange (CBOE), and NASDAQ OMX PHLX (PHLX) call/put volume ratio of 13.67. Ahead of the bell, BOJA is nearly 4% lower.


• ZION, meanwhile, is up 4.7% in electronic trading, after reports the company is undergoing corporate restructuring -- including consolidating into one charter -- was met with a round of upbeat analyst attention. CLSA and Guggenheim, for example, raised their ratings to "buy," while Raymond James and SunTrust Robinson -- among others -- boosted their price targets to $34, territory not charted since November 2008. On the charts, the stock has been gaining ground since hitting an annual low of $23.72 in late January, up 20.6% to trade at $28.60. In the options pits, meanwhile, short-term speculators are more put-skewed than usual. In fact, Zions Bancorporation's Schaeffer's put/call open interest ratio (SOIR) of 1.45 ranks in the 89th percentile of its annual range.


• Roth Capital started VICL with a "buy" rating and $4.65 price target, representing expected upside of 428% to Monday's close at $0.88, and an area not seen by the stock since September 2012. Specifically, the brokerage firm waxed optimistic over Vical Incorporated's pipeline, saying it could present the potential for rapid growth, if successful. The positive outlook has sent shares of VICL up 12% ahead of the bell. Longer term, the security remains a laggard, down nearly 25% year-over-year.

U.S. markets are poised to give back a portion of yesterday's gains this morning, as traders wait to digest updates on motor vehicle sales and factory orders. In company news, today's stocks to watch include discount retailer Dollar General Corp. (NYSE:DG), Detroit darling Ford Motor Company (NYSE:F), and China-based Internet TV provider Youku Tudou Inc (ADR) (NYSE:YOKU). 

• DG reported better-than-expected first-quarter earnings -- though revenue came in slightly below expectations -- and also upped its full-year guidance. As such, the shares are up 5% in pre-market trading, after closing at $72.81 yesterday. Longer term, Dollar General Corp. has performed well, adding more than 34% year-over-year, but recently slipped below its historically supportive 80-day moving average. Meanwhile, recent options traders have been banking on downside, per data from the International Securities Exchange (ISE), Chicago Board Options Exchange (CBOE), and NASDAQ OMX PHLX (PHLX). DG's 10-day put/call volume ratio across this trio of exchanges is 1.00, which ranks in the top quartile of its annual range.


• F announced it will shorten its summer shutdown at a number of manufacturing plants, allowing the company to build an additional 40,000 trucks and SUVs -- including its popular F-150 pickup. However, this positive development has failed to boost the stock ahead of the bell, as it's poised for a slightly lower open. In 2015, Ford Motor Company shares have spun their wheels -- down nearly 1% at $15.36 -- and are staring up at two potential layers of technical resistance.Options traders have caught on to this bearish set-up. During the last 10 weeks at the ISE, CBOE, and PHLX, F has racked up a put/call volume ratio of 0.38 -- higher than 86% of comparable readings from the past 12 months. Separately, F said domestic vehicle sales declined 1% in May on a year-over-year basis.


• Finally, YOKU is partnering with Walt Disney Co (NYSE:DIS) to become the exclusive online marketing partner in China for the latter's Marvel brand. "These partnerships, like the one with Disney, are multifold and give Youku Tudou the opportunity to use its strengths to further its business model and drive future revenue streams through high-quality content, innovative marketing efforts, and merchandising channels," said Youku Tudou Inc CEO Victor Koo. The move is being met with enthusiasm on the Street, as YOKU has gained 1.7% ahead of the bell -- looking to add to its more than 55% year-to-date lead, at $27.64. Short-term traders, however, have been extremely put-skewed toward the equity. YOKU's Schaeffer's put/call open interest ratio (SOIR) of 1.67 sits just 3 percentage points from an annual peak.